Tissue sectioning robot company lands $32M funding

Hawthorne, N.Y.-based medical robotics company Clarapath netted $16 million in follow-on financing after a previous close of $16 million in series B funding, the company said in a Nov. 18 news release.

The company is using the funding to develop its automated tissue sectioning device, SectionStar, in preparation for a launch into the non-clinical lab market, according to the release. Its eventual goal is to launch the device, which aids in the processing and interpretation of human and animal tissues, into the clinical lab market.

"... AI-driven algorithms for interpretation of human tissues — particularly cancer — when examined on a cellular level are vulnerable to the variability in the quality of those tissue cross-sections," Clarapath CEO Eric Feinstein said. "Clarapath's SectionStar consolidates many manual cutting, quality control and decision making steps into one piece of equipment, resulting in better quality tissue sections, faster processing efficiencies, and lower overall costs, all while providing richer data sets on those tissue specimens."

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars